CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
Phase 3
Completed
NCT04205643
| Condition | Ulcerative Colitis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Completed |
|---|
| Enrollment | 548 participants |
|---|
| Interventions | CT-P13 SC (Infliximab), Placebo SC |
|---|
| Start date | Sep 1, 2020 |
|---|
| Completion date | Jul 7, 2022 |
|---|
| Results posted | Sep 28, 2023 |
|---|
Summary
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis
Percentage of Patients Achieving Clinical Remission at Week 54
Week 54 · Participants
| CT-P13 SC 120 mg | 127 Participants |
|---|
| Placebo | 30 Participants |
|---|
| p-value | <0.0001 |
|---|
| Difference estimated using CMH weights | 21.1 (95% CI 11.8–29.3) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.